Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "RAS"

1648 News Found

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
News | November 13, 2023

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions


Bayer posts Q3 2023 Group sales Euro 10.34 billion
News | November 09, 2023

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”


Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
Policy | November 08, 2023

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba

Lack of technology transfer stands out as a formidable barrier


Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia
Policy | October 31, 2023

Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia

India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind


EnginZyme produces key mRNA vaccine ingredient using biocatalysis
Biotech | October 30, 2023

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Drug Approval | October 26, 2023

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients


Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery
News | October 21, 2023

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers


Mandaviya convenes meeting to reiterate the nation’s commitment to addressing gender inequality
Policy | October 21, 2023

Mandaviya convenes meeting to reiterate the nation’s commitment to addressing gender inequality

Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20


Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs
News | October 20, 2023

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months